Research programme: neglected tropical disease therapeutics - Daiichi Sankyo and Drugs for Neglected Diseases initiative

Drug Profile

Research programme: neglected tropical disease therapeutics - Daiichi Sankyo and Drugs for Neglected Diseases initiative

Latest Information Update: 05 Apr 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; Drugs for Neglected Diseases Initiative Foundation
  • Class Antiparasitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease; Leishmaniasis

Most Recent Events

  • 30 Mar 2017 Daiichi Sankyo enters into a joint research agreement with the Drugs for Neglected Diseases initiative for Leishmaniasis and Chagas' disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top